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1. INTRODUCTION {#mgg3725-sec-0005}
===============

Polycystic kidney disease (PKD) is a heterogeneous disease with both autosomal dominant and recessive forms, each with distinct clinical characteristics. The recessive form, known as autosomal recessive polycystic kidney disease (ARPKD), results in end‐stage renal disease (ESRD) and congenital hepatic fibrosis in children (Hartung & Guay‐Woodford, [2014](#mgg3725-bib-0009){ref-type="ref"}; MacRae Dell, [2011](#mgg3725-bib-0014){ref-type="ref"}). In contrast, autosomal dominant polycystic kidney disease (ADPKD), typically presents during adulthood though symptoms may be observed in children and adolescents. The clinical course also results in ESRD as well as hypertension and cysts in several organs (MacRae Dell, [2011](#mgg3725-bib-0014){ref-type="ref"}; Reddy & Chapman, [2017](#mgg3725-bib-0017){ref-type="ref"}).

ADPKD results from pathogenic variants in the *PKD1* (OMIM \*601313) and *PKD2* (OMIM \*173910) genes located on chromosomes 4 and 16, respectively (Reddy & Chapman, [2017](#mgg3725-bib-0017){ref-type="ref"}), while ARPKD is caused by mutations in the *PKHD1* (OMIM \*606702) gene on chromosome 6 (Hartung & Guay‐Woodford, [2014](#mgg3725-bib-0009){ref-type="ref"}). Other syndromes also can cause cysts in the kidneys such as tuberous sclerosis complex (TSC), von Hippel‐Lindau (VHL) disease, and neurofibromatosis type 1 (NF1), but these conditions are associated with other non‐cystic, characteristic features and have different molecular origins than ADPKD and ARPKD (Bonsib, [2009](#mgg3725-bib-0001){ref-type="ref"}; Han & Criado, [2005](#mgg3725-bib-0008){ref-type="ref"}).

While an increased prevalence of several malignancies has been reported in adults with PKD, few cases of children with PKD and pediatric malignancies have been described (Jilg et al., [2013](#mgg3725-bib-0010){ref-type="ref"}; Yu et al., [2016](#mgg3725-bib-0027){ref-type="ref"}). Reports as to whether a diagnosis of PKD is a risk factor for malignancy are conflicting. We present five pediatric patients with PKD who developed a malignancy during childhood, four of whom had histories of ADPKD, and one who represents the first reported case of hepatocellular carcinoma (HCC) diagnosed in a patient with ARPKD.

2. METHODS {#mgg3725-sec-0006}
==========

2.1. Ethical compliance {#mgg3725-sec-0007}
-----------------------

This study was approved by the institutional review board at both institutions prior to data collection.

We describe five patients with a history of PKD that were diagnosed with cancer during childhood at the University of California, Los Angeles Medical Center and the University of Colorado Anschutz Medical Campus. Cases were included from 2012 to 2017 after examining the medical records of patients with PKD during this time period. In order to locate patients in the electronic medical record with PKD and cancer and to find relevant references in the literature, our search criteria included "polycystic kidney disease" OR "autosomal dominant polycystic kidney disease" OR "autosomal recessive polycystic kidney disease" OR "congenital multiple renal cysts" AND "cancer" OR "malignancy."

3. RESULTS {#mgg3725-sec-0008}
==========

3.1. ARPKD case report {#mgg3725-sec-0009}
----------------------

A 5‐year‐old male with a history of kidney transplant secondary to ARPKD and associated congenital hepatic fibrosis was found to have biopsy‐proven HCC with pulmonary metastases. His liver mass initially measured 9.4 × 7.8 cm in the right upper lobe. He received neoadjuvant chemotherapy with cisplatin and doxorubicin, and had a partial response to therapy. This was followed by right liver lobectomy with negative tissue margins. The patient subsequently received seven cycles of adjuvant chemotherapy with vincristine, temozolamide, and irinotecan as well as thoracotomy to remove the remaining pulmonary nodules. His alpha‐fetoprotein decreased from 263,500 to 2.2 ng/ml after 14 months with ongoing evidence of complete remission by surveillance imaging. As of the latest follow‐up visit 17 months off‐therapy, the patient remains well and free of disease.

*PKHD1* gene sequencing identified two compound heterozygous pathogenic variants. One variant results in a frameshift mutation and a truncated protein that is expected to cause disease, but has not been previously reported in the literature (Table [1](#mgg3725-tbl-0001){ref-type="table"}). The other variant is a substitution that causes an amino acid change, and has been described before in another individual with ARPKD (Krall et al., [2014](#mgg3725-bib-0012){ref-type="ref"}).

###### 

Characteristics of patients with a history of PKD who developed a malignancy

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient   Age at cancer diagnosis   Gender   PKD type   PKD\                            Other genetic test results                                                  Malignancy type
                                                          variant                                                                                                     
  --------- ------------------------- -------- ---------- ------------------------------- --------------------------------------------------------------------------- ----------------------------
  1         5 years                   Male     ARPKD      *PKHD1*\                        No abnormalities identified by chromosomal microarray                       Hepatocellular carcinoma
                                                          c.7967_7968delCA                                                                                            

  2         17 years                  Male     ADPKD      *PKD1*\                         No other variants identified by whole exome sequencing                      Testicular germ cell tumor
                                                          c.1723−1G \> A                                                                                              

  3         15 years                  Male     ADPKD      *PKD1*\                         No other variants identified by whole exome sequencing                      Testicular germ cell tumor
                                                          c.1723−1G \> A                                                                                              

  4         6 months                  Female   ADPKD      Genetic testing not performed   Homozygous deletions of *SMARCB1* in tumor, both alleles present in blood   Renal rhabdoid tumor

  5         8 years                   Female   ADPKD      *PKD2*\                         *TSC1*, *TSC2, PKD1* sequencing---no pathogenic variants detected           PEComa
                                                          c.339delG                                                                                                   
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; ARPKD, autosomal recessive polycystic kidney disease; PEComa, perivascular epithelioid cell tumor; PKD, polycystic kidney disease; PKD1, polycystic kidney disease 1. GenBank Accession NM_001009944.2; PKD2, polycystic kidney disease 2. GenBank Accession NM_000297.3; PKHD1, polycystic kidney and hepatic disease 1. GenBank Accession NM_138694.3.
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3.2. ADPKD case series {#mgg3725-sec-0010}
----------------------

Four children with a history of ADPKD developed cancers during childhood. Two of these children (Cases 2 and 3) are siblings and were diagnosed with familial testicular germ cell tumors. The other two children with ADPKD were diagnosed with renal rhabdoid tumor (Case 4) and perivascular epithelioid cell tumor (PEComa) arising from the ligamentum teres with liver metastases (Case 5). At last follow‐up visit, all patients remain alive.

Case 2 and 3 were found to have the same mutation in *PKD1* that has been described previously (Truscott et al., [2017](#mgg3725-bib-0025){ref-type="ref"}). Case 4 did not have genetic testing for PKD, but has a strong family history of ADPKD and a personal history of multiple renal cysts. Case 5 had genetic testing for TSC since PEComas and renal cysts have been reported in TSC (Dickson, Schwartz, Antonescu, Kwiatkowski, & Malinowska, [2013](#mgg3725-bib-0004){ref-type="ref"}), however, sequencing and deletion/duplication analysis detected no mutations. Instead, a pathogenic variant in *PKD2* that resulted in a frameshift was detected. Further details are illustrated in Table [1](#mgg3725-tbl-0001){ref-type="table"}.

3.3. Prevalence of cancer in children with PKD {#mgg3725-sec-0011}
----------------------------------------------

Our search of the electronic medical records at our two centers identified 392 children with PKD from 2011 to 2015, and only five patients had a diagnosis of cancer. This translates to an incidence rate of 260 per 100,000 people with PKD per year.

4. DISCUSSION {#mgg3725-sec-0012}
=============

In this report, we describe five patients with an underlying diagnosis of ADPKD or ARPKD who developed four different malignancy types during childhood. These patients had no other identified cancer predisposition syndromes, but did have confirmed diagnoses of PKD. This series also includes the first reported patient with ARPKD to develop HCC who had a novel pathogenic variant detected in the *PKHD1* gene. While the association of malignancy in PKD is unclear, patients\' families were certainly impacted as they wondered if additional family members with this diagnosis might be at risk for cancer in the future.

Prior reports of malignancies in children with a history of PKD are limited. This includes a case of hepatoblastoma and pleuropulmonary blastoma that developed in two separate patients with a history of ARPKD (Luoto, Pakarinen, Jahnukainen, & Jalanko, [2014](#mgg3725-bib-0013){ref-type="ref"}; Traubici, Somers, Ling, Pearl, & Nathan, [2011](#mgg3725-bib-0024){ref-type="ref"}). Tumors associated with TSC have also been observed as TSC and PKD may occur together due to the concurrent deletion of both *PKD1* and *TSC2* (OMIM \*191092) genes that are adjacent to chromosome 16 (Rijal, Dhakal, Giri, & Dahal, [2014](#mgg3725-bib-0018){ref-type="ref"}). Surprisingly, although PEComas are known to be associated with TSC, no pathogenic variants in the *TSC1* (OMIM \*605284) nor *TSC2* genes were detected in Case 5 (Dickson et al., [2013](#mgg3725-bib-0004){ref-type="ref"}).

In contrast to the rare reports of malignancies in children diagnosed with PKD, solid tumors have been described in several studies in adults with PKD, suggesting an age‐related increased risk for malignancy. Mutations in the genes encoding polycystin‐1 and polycystin‐2 are responsible for ADPKD, and have been associated with oncogenesis (Gargalionis et al., [2015](#mgg3725-bib-0007){ref-type="ref"}). One study that reviewed surgically removed kidneys in patients with a history of ADPKD found that 5% of the lesions were malignant (Jilg et al., [2013](#mgg3725-bib-0010){ref-type="ref"}). Conversely, ARPKD is the result of mutations in *PKHD1*, whose protein polyductin is not known to increase the risk for malignancy, yet cases of cholangiocarcinoma have been reported in adults with ARPKD (Fonck, Chauveau, Gagnadoux, Pirson, & Grünfeld, [2001](#mgg3725-bib-0006){ref-type="ref"}). The specific mutations described in this cohort have not been associated with cancer in other reported cases of PKD. More convincing, a large retrospective study found that there was an increased risk of several cancer subtypes in patients with PKD when compared to a cohort of patients without PKD (Yu et al., [2016](#mgg3725-bib-0027){ref-type="ref"}). Two potential confounding factors that were not considered in the prior studies included a patient\'s history of renal dysfunction or solid organ transplantation, yet both have been associated with an increased risk of malignancy (Doycheva, Amer, & Watt, [2016](#mgg3725-bib-0005){ref-type="ref"}; Russo, [2012](#mgg3725-bib-0019){ref-type="ref"}). Among our patients, only case 1 should be mentioned as he had a kidney transplant nearly 2 years prior to his diagnosis of HCC.

These patients were all worked up for likely cancer predisposition syndromes, but no mutations were found to suggest a genetic predisposition in any of the cases. However, complete genetic profiling was not performed for any of our patients. ADPKD is relatively common in the adult population, and the estimated prevalence of solid tumors in this population appears to be higher than in the general population. While we cannot prove that ARPKD and ADPKD was the underlying cause of malignancy in our patients, given the rarity of the tumors especially in pediatrics, it seems possible that they may be associated with oncogenesis.

Further supporting our hypothesis is the high incidence of cancer that we have described in children with PKD at our two centers. Our data suggest an estimated incidence of 260 cases of cancer per 100,000 children with PKD per year, that is significantly higher than the incidence of childhood cancer (age 0--19 years) in the general population (18.2 per 100,000 per year) according to the most recent available SEER data (SEER, [2018](#mgg3725-bib-0023){ref-type="ref"}). However, our estimate is likely greater than expected, given that ADPKD is frequently asymptomatic during childhood and therefore, it is possible that some children may have died from their malignancy without knowing that they also had a genetic diagnosis of PKD. In addition, a recent meta‐analysis revealed that ADPKD is likely an under‐recognized condition, confirming that while still rare, the diagnosis is often missed and is more common than previously reported (Solazzo et al., [2018](#mgg3725-bib-0022){ref-type="ref"}). Therefore, while there are few reported cases of malignancy associated with PKD, the magnitude of cancer risk may be significant.

Although the pathogenesis of PKD shares many similarities with malignant proliferation, some studies have shown that these cystic lesions are not associated with the development of malignancy, and may actually be protective (Orskov, Sørensen, Feldt‐Rasmussen, & Strandgaard, [2012](#mgg3725-bib-0016){ref-type="ref"}; Seeger‐Nukpezah, Geynisman, Nikonova, Benzing, & Golemis, [2015](#mgg3725-bib-0020){ref-type="ref"}; Wetmore et al., [2014](#mgg3725-bib-0026){ref-type="ref"}). Yet, our reported cases suggest the possibility that the genetic mutations present in PKD may play a role in driving oncogenesis especially given the rarity of cancer in children. This seems most probable in ADPKD given the increased development of both cysts and malignancies in several other autosomal dominant cancer predisposition syndromes, for example, NF1, TSC, VHL (Crespigio et al., [2018](#mgg3725-bib-0003){ref-type="ref"}; Kandt, [2003](#mgg3725-bib-0011){ref-type="ref"}). All of these syndromes involve alterations of genes in the mammalian target of rapamycin (mTOR) pathway, which is known to regulate cell proliferation and differentiation. Moreover, polycystin‐1 has specifically been implicated in this pathway (Shillingford et al., [2006](#mgg3725-bib-0021){ref-type="ref"}). Animal models of PKD have also shown upregulation and phosphorylation of cancer associate tyrosine kinases including AKT, ERK, B‐Raf, and Src (Nagao, Kugita, Yoshihara, & Yamaguchi, [2012](#mgg3725-bib-0015){ref-type="ref"}). In Figure [1](#mgg3725-fig-0001){ref-type="fig"}, we illustrate multiple genetic pathways including mTOR and several pathologic processes that have been described in cancer development and PKD. The overlap of these pathways suggests that patients with PKD may harbor alterations in the mTOR signaling pathways and have a higher risk for developing a malignancy than individuals in the general population.

![Signaling pathways present in the development of PKD that may promote oncogenesis (Chapin & Caplan, [2010](#mgg3725-bib-0002){ref-type="ref"}; Nagao et al., [2012](#mgg3725-bib-0015){ref-type="ref"}; Seeger‐Nukpezah et al., [2015](#mgg3725-bib-0020){ref-type="ref"})](MGG3-7-e00725-g001){#mgg3725-fig-0001}

Further research evaluating children with PKD prospectively and evaluating the incidence of cancer would potentially address this question. Such studies could include examining the prevalence of solid tumors in patients with ADPKD at our institutions in order to help determine the significance of our findings. If there truly is an increased risk to develop cancer in children with PKD, increased surveillance may be warranted to detect cancer at an early stage, or prevent tumors from becoming malignant. Additionally, gaining a better understanding of the molecular and biochemical mechanism of pediatric malignancy in the context of PKD could elucidate improved options for chemoprevention and/or treatment.
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